Slingshot members are tracking this event:

FDA Completes Post Action Meeting with Lipocine (LPCN) Regarding LPCN 1021 in Testosterone Replacement Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Post Action Meeting, Lpcn 1021, Testosterone Replacement Therapy, Hypogonadism